A Series of Beta-Carboline Derivatives Inhibit the Kinase Activity of PLKs

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Han, Xiaomin ^a   Zhang, Jing ^a   Guo, Liang ^b   Cao, Rihui ^b   Li, Yongzhen ^a   Li, Ni ^a   Ma, Qin ^b   Wu, Jialin ^b   Wang, Yanchang ^c   Si, Shuyi ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Xinjiang Huashidan Pharmaceutical Co   (China)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CARBOLINE DERIVATIVE; CELL PROTEIN; DH281; DH285; DH287; POLO LIKE KINASE; POLO LIKE KINASE 1; POLO LIKE KINASE 2; POLO LIKE KINASE 3; PROTEIN WEE1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS; MITOSIS SPINDLE; S PHASE CELL CYCLE CHECKPOINT;

APOPTOSIS; CARBOLINES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

MAMMALIA;

EID: 84867093421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046546     Document Type: Article

References (47)

1. Liamazares S, Moreira A, Tavares A, Girdham C, Spruce BA, et al. (1991) Polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev 5: 2153-2165.
2. Barr FA, Silljé HHW, Nigg EA, (2004) Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429-440.
3. Lane HA, Nigg EA, (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135: 1701-1713.
4. van Vugt MATM, van de Weerdt B, Vader G, Janssen H, Calafat J, et al. (2004) Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 279: 36841-36854.
5. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, et al. (2005) Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 446: 442-450.
6. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, et al. (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94: 148-152.
7. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, et al. (1999) Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 15: 687-692.
8. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, et al. (2001) Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 169: 41-49.
9. Knecht R, Elez R, Oechler M, Solbach C, Ilberg C, et al. (1999) Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59: 2794-2797.
10. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, et al. (1997) Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14: 543-549.
11. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, et al. (2001) Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 164: 41-49.
12. Gray PJ, Bearss DJ, Han H, Nagle R, Tsao MS, et al. (2004) Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3: 641-646.
13. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, et al. (2002) Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 29: 354-358.
14. Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, et al. (2002) Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21: 3162-3171.
15. Liu X, Erikson RL, (2003) Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 100: 5789-5794.
16. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, et al. (2005) Small Interfering RNA-Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals. Cancer Res 65: 2698-2704.
17. Cogswell JP, Brown CE, Bisi JE, Neill SD, (2000) Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 11: 615-623.
18. Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K, (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94: 1863-1877.
19. Spänkuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, et al. (2004) Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96: 862-872.
20. Chen XH, Lan B, Qu Y, Zhang XQ, Cai Q, et al. (2006) Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. World J Gastroenterol 12: 29-35.
21. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, et al. (2005) Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 115: 978-985.
22. Liu X, Lei M, Erikson RL, (2006) Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26: 2093-2108.
23. Schöffski P, (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14: 559-570.
24. Strebhardt K, (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9: 643-660.
25. McInnes C, Mezna M, Fischer PM, (2005) Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 5: 181-197.
26. Schmit TL, Ahmad N (2007) Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther 6: 1920.
27. Schöffski P, (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. The Oncologist 14: 559-570.
28. McInnes C, Mezna M, Fischer PM, (2005) Progress in the discovery of polo-like kinase inhibitors. Current Topics in Medicinal Chemistry 5: 181-197.
29. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, et al. (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26: 5511-5517.
30. Olmos D, Allred A, Sharma R, Brunetto A, Smith D, et al. (2009) Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. J Clin Oncol 27S.
31. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, et al. (2008) Phase I study of ON 01910. Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 26: 5504-5510.
32. Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD, (2006) A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1-Interacting Properties, in Patients with Advanced Solid Tumors. Clin Cancer Res 12: 5182-5189.
33. Liu H, Wang Y (2006) The function and regulation of budding yeast Swe1 in response to interrupted DNA synthesis. Mol Biol Cell: E5-E11.
34. Zhang J, Li Y, Guo L, Cao R, Zhao P, et al. (2009) DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. Cancer Biol Ther 8: 2374-2383.
35. Song B, Liu XS, Davis K, Liu X, (2011) Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress. Mol Cell Biol 31: 4844-4856.
36. Sumara I, Giménez-Abián JF, Gerlich D, Hirota T, Kraft C, et al. (2004) Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 14: 1712-1722.
37. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, et al. (2004) M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc Natl Acad Sci U S A 101: 4419-4424.
38. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E, (2001) Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410: 215-220.
39. Strebhardt K, (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9: 643-660.
40. Ishida J, Wang HK, Bastow KF, Hu CQ, Lee KH, (1999) Antitumor agents 201.1 Cytotoxicity of harmine and beta-carboline analogs. Bioorg Med Chem Lett 9: 3319-3324.
41. Winkles JA, Alberts GF, (2005) Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24: 260-266.
42. Sobhani AM, Ebrahimi SA, Mahmoudian M, (2002) An In vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its a-Carboline alkaloids. J Pharm Pharm Sci 5: 19-23.
43. Deveau AM, Labroli MA, Dieckhaus CM, Barthen MT, Smith KS, et al. (2001) The synthesis of amino-acid functionalized [beta]-Carbolines as topoisomerase II inhibitors. Bioorg Med Chem Lett 11: 1251-1255.
44. Song Y, Kesuma D, Wang J, Deng Y, Duan J, et al. (2004) Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun 317: 128-132.
45. Li Y, Liang F, Jiang W, Yu F, Cao R, et al. (2007) DH334, a beta-carboline anti-cancer drug, inhibits the CDK activity of budding yeast. Cancer Biol Ther 6: 1193-1199.
46. Lénárt P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, et al. (2007) The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 17: 304-315.
47. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, et al. (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316-322.